Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-207-6 | CAS number: 104-49-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The read across for PPDI; is based upon the analogous substances to which basic form, degree of substitution of functional groups is not considered to effect the proposed read across for the endpoint of repeated dose toxicity.
The animals were whole body exposed to 0, 0.05 and 0.15 ppm of TDI (80/20) vapour for 6 hours/day, 5 days/week. In both species, body weight gain was reduced at 0.15 ppm over the first 12 weeks that persisted but did not worsen over the remaining period of the study. In rats, rhinitis was observed in males at 0.15 ppm and in females beginning at 0.05 ppm, generally characterized by squamous metaplasia/hyperplasia of the respiratory mucosa, with and without exudate in the lumen, and leucocyte infiltration in the lamina propria. This finding is considered to be due to local irritation of the anterior nasal cavity. In mice, histopathology revealed marked inflammatory processes in trachea, larynx, bronchi, lungs and predominantly in nasal turbinates (chronic and necrotic rhinitis) of male and female animals beginning at 0.05 ppm. Therefore, the LOAEC for rats and mice is 0.05 ppm (0.362 mg/m3) after long-term inhalation of TDI vapour.
Inhalation exposure is the most appropriate route for assessing occupational risk in humans. Effects from repeated exposure of animals to TDI are limited to effects on the respiratory tract caused by local irritation, no signs of systemic toxicity were observed.
Simultaneously, other studies show that nose is the targeted organ of the respiratory system. Thus, the assessment confirmed the legal classification of the substance as STOT Single Exp.3 (Hazard statement H335, May cause respiratory irritation).
Key value for chemical safety assessment
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: inhalation
- Remarks:
- combined repeated dose and carcinogenicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1976-10 to 1978-11
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- yes
- Remarks:
- 2 doses investigated
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- As specified above.
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- As per the guideline.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Age at study initiation: 8 - 9 weeks
- Housing: 6 ♂ / 6 ♀ per cage - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: Unchanged
- Remarks:
- No vehicle
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION:
- Method of holding animals in test chamber: Animals were housed 6 ♂ / 6 ♀ per cage and exposed in 9 m³ chambers.
- Method of conditioning air: Passage of dry nitrogen through liquid TDI maintained at 21°C. The vapour produced was then diluted with air in all-glass systems to produce the desired exposure concentration.
OTHER:
Because of the known chemical reactivity and thus its potential storage instability, TDI lots were renewed every three months and fresh TDI was placed in the respective vapour-generating apparatus at the beginning of each daily exposure period. The measured mean test concentrations of TDI were 0.052 ppm and 0.146 ppm over a period of up to 113 weeks, with standard deviations of 0.007 ppm and 0.014 ppm, respectively. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- 5/day, each exposure group.
U.E.I. Model 7000 TDI tape monitor and the Marcali colorimetric method. - Duration of treatment / exposure:
- 6 h / day
- Frequency of treatment:
- daily, 5 days per week, up to 113 weeks. No post exposure period.
- Dose / conc.:
- 0.05 ppm (nominal)
- Dose / conc.:
- 0.15 ppm (nominal)
- No. of animals per sex per dose:
- 126
- Control animals:
- yes, sham-exposed
- Details on study design:
- As per guideline.
- Positive control:
- None; not applicable.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
BODY WEIGHT: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
HAEMATOLOGY: Yes
CLINICAL CHEMISTRY: Yes
URINALYSIS: Yes
Interim sacrifices were performed after 6, 12, and 18 months of exposure consisting of 7 animals/sex/dose. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
ORGAN WEIGHTS: Yes
Other examinations: Special histopathology of the nasal cavity. - Statistics:
- Survival probabilities for each group were calculated by the method of Kaplan and Meier (J. Am. Statist. Ass. 53: 457 (1958)). The survival of the individual treatment groups was compared using the log rank method of Peto and Pike (Biometrics 29: 579 (1973)).
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Compared to control rats, there were significantly reduced body weight gains in males and in females of the highest dose groups up to study week 12 that remained significantly reduced throughout the study for female rats.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In rats sacrificed as scheduled (interim sacrifices after 6, 12 and 18 months + terminal sacrifice), lesions were localized primarily in the anterior respiratory mucosa of the nasal cavity. Rhinitis was increased in incidence and severity (grades1-4: minimal - marked rhinitis, generally characterized by squamous metaplasia and hyperplasia of the epithelium, leucocyte infiltration in the lamina propria and exudate in the lumen) in a dose-dependent manner and is considered to be due to local irritation.
- Histopathological findings: neoplastic:
- no effects observed
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.15 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical signs
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- < 0.05 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 0.15 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical signs
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 0.05 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- Key result
- Critical effects observed:
- no
- Conclusions:
- The animals were whole body exposed to 0, 0.05 and 0.15 ppm of TDI (80/20) vapour for 6 hours/day, 5 days/week. In both species, body weight gain was reduced at 0.15 ppm over the first 12 weeks that persisted but did not worsen over the remaining period of the study. In rats, rhinitis was observed in males at 0.15 ppm and in females beginning at 0.05 ppm, generally characterized by squamous metaplasia/hyperplasia of the respiratory mucosa, with and without exudate in the lumen, and leucocyte infiltration in the lamina propria. This finding is considered to be due to local irritation of the anterior nasal cavity. In mice, histopathology revealed marked inflammatory processes in trachea, larynx, bronchi, lungs and predominantly in nasal turbinates (chronic and necrotic rhinitis) of male and female animals beginning at 0.05 ppm. Therefore, the LOAEC for rats and mice is 0.05 ppm (0.362 mg/m3) after long-term inhalation of TDI vapour.
Inhalation exposure is the most appropriate route for assessing occupational risk in humans. Effects from repeated exposure of animals to TDI are limited to effects on the respiratory tract caused by local irritation, no signs of systemic toxicity were observed.
Simultaneously, other studies show that nose is the targeted organ of the respiratory system. Thus, the assessment confirmed the legal classification of the substance as STOT Single Exp.3 (Hazard statement H335, May cause respiratory irritation). - Executive summary:
The animals were whole body exposed to 0, 0.05 and 0.15 ppm of TDI (80/20) vapour for 6 hours/day, 5 days/week. In both species, body weight gain was reduced at 0.15 ppm over the first 12 weeks that persisted but did not worsen over the remaining period of the study. In rats, rhinitis was observed in males at 0.15 ppm and in females beginning at 0.05 ppm, generally characterized by squamous metaplasia/hyperplasia of the respiratory mucosa, with and without exudate in the lumen, and leucocyte infiltration in the lamina propria. This finding is considered to be due to local irritation of the anterior nasal cavity. In mice, histopathology revealed marked inflammatory processes in trachea, larynx, bronchi, lungs and predominantly in nasal turbinates (chronic and necrotic rhinitis) of male and female animals beginning at 0.05 ppm. Therefore, the LOAEC for rats and mice is 0.05 ppm (0.362 mg/m3) after long-term inhalation of TDI vapour.
Inhalation exposure is the most appropriate route for assessing occupational risk in humans. Effects from repeated exposure of animals to TDI are limited to effects on the respiratory tract caused by local irritation, no signs of systemic toxicity were observed.
Simultaneously, other studies show that nose is the targeted organ of the respiratory system. Thus, the assessment confirmed the legal classification of the substance as STOT Single Exp.3 (Hazard statement H335, May cause respiratory irritation).
- Endpoint:
- chronic toxicity: inhalation
- Remarks:
- combined repeated dose and carcinogenicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- 1. Source and target substances
The substances m-tolylidene diisocyanate (CAS No 26471-62-5, consisting of 80% tolylidene 2,4-
diisocyanate and 20% tolylidene 2.6-diisocyanate, hereafter referred to as TDI,source) and pphenylene
diisocyanate (CAS No 104-49-4, hereafter referred to as p-PDI, target) each consist of a
diisocyanate substituted benzene ring. The substituents on the phenyl ring are almost identical in
both cases, with the TDI being substituted in a meta-fashion with the two isocyanate groups, while
the p-PDI features the substituents in a para-fashion. Aside from this, the TDI features an additional
methyl substituent on the phenyl ring, which is absent in the p-PDI.
2. Description of the scenario
In the ECHA RAAF document 6 different read-across approaches are described in the form of
“scenarios”. The scenarios thereby categorize the type of read-across approach used to allow a
systematic assessment of the crucial scientific aspects. Each scenario comprises different
“assessment elements”, which address different scientific considerations deemed crucial to judge the
validity and the reliability of read-across.
In the present case, the read-across approach of m-tolylidene diisocyanate (TDI) and p-phenylene
diisocyanate (p-PDI) corresponds with scenario 2.
This scenario covers the analogue approach (read-across is employed between a small number of
structurally-similar substances; there is no trend or regular pattern on the properties) for which the
read-across hypothesis is based on qualitative similar properties of the compounds.
3. Read Across Hypothesis
The read-across approach should be used for data gap filling of p-phenylene diisocyanate (p-PDI)
using fate, ecotoxicitiy and human health toxicity studies of m-tolylidene diisocyanate (TDI). Based
on the similar chemical structure and the available experimental data both substances are highly
reactive diisocyanates. The chemical reactions known for the highly reactive diisocyanates (e.g. rapid
hydrolysis to the diamine in aqueous environments, polymerization reactions and reactions with
amines or hydroxyl groups in biological specimens) are reported for TDI (MAK 2003, ECHA 2013)
and can be assumed to take place also when p-PDI enters an organism. Both compounds consist of
a benzene ring and two isocyanate groups. TDI is substituted in a meta-fashion with the two
isocyanate groups, while the p-PDI features the substituents in a para-fashion. The differences in the
substitution pattern (meta versus para) do not lead to a difference in reactivity of the highly reactive
isocyanate groups.
It is reasonable to assume and experimentally verified that both compounds have nearly identical
behavior in physico-chemical and (eco)toxicological studies. Therefore there should be almost no
differentiation between effects of target and source substance.
4. Data Matrix
Please refer to Section 13.2 "Other Assessment reports" for full justification, reference "pPDI+TDI READ ACROSS JUSTIFICATION". - Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 0.15 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical signs
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- < 0.05 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 0.15 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical signs
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 0.05 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- clinical signs
- Key result
- Critical effects observed:
- no
- Conclusions:
- The read across for pPDI; is based upon the analogous substances to which basic form, degree of substitution of functional groups is not considered to effect the proposed read across for the endpoint of repeated dose toxicity.
Inhalation exposure is the most appropriate route for assessing occupational risk in humans. Effects from repeated exposure of animals to TDI are limited to effects on the respiratory tract caused by local irritation, no signs of systemic toxicity were observed.
Simultaneously, other studies show that nose is the targeted organ of the respiratory system. Thus, the assessment confirmed the legal classification of the substance as STOT Single Exp.3 (Hazard statement H335, May cause respiratory irritation). - Executive summary:
The read across for pPDI; is based upon the analogous substances to which basic form, degree of substitution of functional groups is not considered to effect the proposed read across for the endpoint of repeated dose toxicity.
Inhalation exposure is the most appropriate route for assessing occupational risk in humans. Effects from repeated exposure of animals to TDI are limited to effects on the respiratory tract caused by local irritation, no signs of systemic toxicity were observed.
Simultaneously, other studies show that nose is the targeted organ of the respiratory system. Thus, the assessment confirmed the legal classification of the substance as STOT Single Exp.3 (Hazard statement H335, May cause respiratory irritation).
Referenceopen allclose all
Chronic Toxicity:
No exposure-related clinical signs of toxicity were observed during the study. No treatment-related changes in hematology, blood biochemistry, urinalyses, ophthalmoscopy or organ weights were recorded.
Compared to control rats, there were significantly reduced body weight gains in males and in females of the highest dose groups up to study week 12 that remained significantly reduced throughout the study for female rats. Mortality occurred in both test and control groups, with generally higher mortality rates at earlier time points in test groups than in the controls for males, providing additional supporting evidence indicating that MTD was reached.
Table 1: Body weight gain and mortality rate of rats during exposure
Males |
Females |
|||||
Control |
Low dose |
High dose |
Control |
Low dose |
High dose |
|
Group mean body weight gain (g): week 0 –12 |
298 |
296 |
275* |
136 |
132 |
121* |
Group mean body weight gain (g): week 0 - termination |
554 |
579 |
525 |
395 |
378 |
345* |
Mortality before interim sacrifice after 6 m |
3/126 |
13/126 |
11/126 |
0/126 |
1/126 |
0/126 |
Mortality before interim sacrifice after 12 m |
4/116 |
1/106 |
1/108 |
1/119 |
3/118 |
1/119 |
Mortality before interim sacrifice after 18 m |
7/105 |
8/97 |
13/100 |
14/111 |
20/108 |
9/110 |
Mortality before terminal sacrifice |
52/89 |
46/81 |
50/80 |
53/88 |
55/81 |
46/84 |
* P <0.01 when compared to the controls
In rats sacrificed as scheduled (interim sacrifices after 6, 12 and 18 months + terminal sacrifice), lesions were localized primarily in the anterior respiratory mucosa of the nasal cavity. Rhinitis was increased in incidence and severity (grades1-4: minimal - marked rhinitis, generally characterized by squamous metaplasia and hyperplasia of the epithelium, leucocyte infiltration in the lamina propria and exudate in the lumen) in a dose-dependent manner and is considered to be due to local irritation.
Table 2: Incidence of rhinitis in the anterior nasal cavity of rats
Males |
Females |
|||||
Control |
Low dose |
High dose |
Control |
Low dose |
High dose |
|
Grade 0* |
30/58 |
30/55 |
6/51 |
46/56 |
27/47 |
17/57 |
Grade 1* |
11/58 |
7/55(13 %) |
5/51 |
7/56 |
8/47(17 %) |
16/57(28 %) |
Grade 2* |
13/58 |
15/55 (27 %) |
13/51(25 %) |
3/56 |
9/47(19 %) |
18/57(32 %) |
Grade 3* |
4/58 |
3/55 |
23/51 (45 %) |
0 |
3/47(6 %) |
5/57(9 %) |
Grade 4* |
0 |
0 |
4/51 |
0 |
0 |
0 |
No section |
0 |
0 |
0 |
0 |
2 |
|
Percent rats with grade1- 4 rhinitis |
48 % |
45 % |
88 % |
18 % |
43 % |
70 % |
* Grade 0 = unremarkable; Grade 1 = minimal rhinitis, Grade 2 = slight rhinitis, Grade 3 = moderate rhinitis, Grade 4 = marked rhinitis generally characterized by squamous metaplasia and hyperplasia of the epithelium, leucocyte infiltration in the lamina propria and exudate in the lumen
Carcinogenicity
With respect to the assessment of tumour formation, there were slight increases in the tumour incidence for some locations when compared to the incidence in the controls. In Table 1, specific tissues and the number of tumours in the various treatment and control groups are listed only if there were at least two more tumours in the groups treated with TDI than in the controls. The author concluded, that the type and incidence of tumours and the numbers of tumour-bearing rats were similar in both control and TDI treated groups.
A statistical analysis of the results was not carried out, but the tumour spectrum in all groups was in the range of the general experience (Loeser, 1983). A full assessment of the original tumour data by both the protocolled method and more current methodology has been reported by Müller (2008). Overall, and taking into account the statistical results, contemporary control animal data from the laboratory and the tumour profiles of the animal strain used, Müller concluded that there was no toxicologically significant increase in the tumour incidences of this long-term TDI rat study.
The overall evaluation of the study therefore led to the conclusion, that TDI is not carcinogenic in rats under the conditions described.
Table 1: Tumour incidences of the 2-year rat study with TDI (80/20)
TDI (ppm) |
Sex |
0 |
0.05 |
0.15 |
Number of animals investigated |
M/F |
104/104 |
104/105 |
104/105 |
Types of tumours for which there were at least 2 more tumours in the groups treated with than in the controls: |
||||
Adenomas (skin) |
M |
0 |
0 |
3 |
Papillomas (skin) |
F |
1 |
3 |
3 |
Benign tumours (mammary gland) |
F |
24 |
27 |
22 |
Carcinomas (mammary gland) |
F |
9 |
9 |
14 |
Fibromas (subcutis/muscle/bones) |
M/F |
29/1 |
22/1 |
35/4 |
Histiocytomas (subcutis/muscle/bones) |
M |
1 |
4 |
1 |
Malignant lymphomas (haematopoietic system) |
F |
1 |
1 |
3 |
Haemangiomas (haematopoietic system) |
M |
1 |
1 |
4 |
Islet cell adenomas (pancreas) |
M |
1 |
2 |
3 |
Adenomas (pituitary gland) |
F |
64 |
62 |
67 |
Meningiomas (brain) |
M |
0 |
0 |
2 |
Lipomatous tumours (kidney) |
M |
1 |
3 |
0 |
M = male; F = female
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEC
- 0.362 mg/m³
- Study duration:
- chronic
- Experimental exposure time per week (hours/week):
- 113
- Species:
- rat
- System:
- other: chonic toxicity.
Additional information
Justification for classification or non-classification
The substance has to be classified to hazard class STOT-SE3 according to CLP Regulation 1272/200.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.